ALNY Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$245.44 |
| 52 Week High | US$304.39 |
| 52 Week Low | US$141.98 |
| Beta | 0.32 |
| 1 Month Change | -1.35% |
| 3 Month Change | -10.38% |
| 1 Year Change | 28.49% |
| 3 Year Change | 26.29% |
| 5 Year Change | 108.81% |
| Change since IPO | 3,983.86% |
Recent News & Updates
Recent updates
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You
Dec 16
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Oct 27Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 12Alnylam: HELIOS-B Success Priced In Already
Aug 30Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results
Aug 04Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher
Aug 02RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Shareholder Returns
| ALNY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.6% | -3.5% |
| 1Y | 28.5% | -1.5% | 22.1% |
Return vs Industry: ALNY exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: ALNY exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALNY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALNY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,100 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| ALNY fundamental statistics | |
|---|---|
| Market cap | US$30.81b |
| Earnings (TTM) | -US$332.26m |
| Revenue (TTM) | US$2.09b |
15.1x
P/S Ratio-95.3x
P/E RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNY income statement (TTM) | |
|---|---|
| Revenue | US$2.09b |
| Cost of Revenue | US$306.41m |
| Gross Profit | US$1.79b |
| Other Expenses | US$2.12b |
| Earnings | -US$332.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.58 |
| Gross Margin | 85.37% |
| Net Profit Margin | -15.86% |
| Debt/Equity Ratio | 7,566.4% |
How did ALNY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alnylam Pharmaceuticals, Inc. is covered by 66 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| Emily Bodnar | Berenberg |